All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Where does carfilzomib fit in the current MM treatment landscape?

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked, Where does carfilzomib fit in the current multiple myeloma (MM) treatment landscape?

Where does carfilzomib fit in the current MM treatment landscape?

In this video, Schmidt discusses the selective proteasome inhibitor carfilzomib and its potential role in treating patients with high-risk MM after the results presented this year. He discusses carfilzomib in combination with immunomodulatory drugs and in the treatment of early relapsed/refractory (R/R) MM, especially for lenalidomide and/or bortezomib-refractory disease. Lastly, he mentions the clinical trials ENDURANCE (NCT01863550) and CLARION (NCT01818752) which are both phase III studies evaluating carfilzomib in newly diagnosed MM patients.